Cara L Macfarlane
Overview
Explore the profile of Cara L Macfarlane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murray R, Macfarlane C
J CME
. 2024 Jun;
13(1):2361404.
PMID: 38831938
There was a renewed vigour among the participants attending the 16th Annual European CME Forum (#16ECF), which took place in the Hague, the Netherlands from 8-10 November 2023. This emanated...
2.
Jacobson A, Macfarlane C, Pozniak E
J Eur CME
. 2020 Nov;
9(1):1834762.
PMID: 33178490
Mobile health (mHealth) technologies such as smartphone applications are increasingly being adopted in the healthcare setting to support the delivery of evidence-based care. Given the approaching ubiquity of mHealth tools...
3.
Report on Proceedings of the 12th Annual European CME Forum, University of Manchester, November 2019
Murray R, Macfarlane C
J Eur CME
. 2020 May;
9(1):1754121.
PMID: 32373398
The 12th Annual European CME Forum (#12ECF) was held 6-8 November 2019 at the Barnes Wallis building in the University of Manchester, Manchester, UK. An international group of attendees participated...
4.
Macfarlane C, Quek S, Pionnier N, Turner J, Wanji S, Wagstaff S, et al.
Sci Rep
. 2020 Apr;
10(1):6672.
PMID: 32317658
Skin snip evaluation for onchocerciasis has insufficient sensitivity when skin microfilarial (mf) densities are low, such as following ivermectin treatment. Mf density is suitable for assessing microfilaricidal efficacy but only...
5.
Macfarlane C, Dean L, Thomson R, Garner P
J Glob Health
. 2019 Oct;
9(2):020414.
PMID: 31662849
Background: Mass drug administration (MDA) programmes for neglected tropical diseases (NTDs) depend on voluntary community drug distributors (CDDs) to deliver drugs, and these volunteer schemes need regular training and supervision....
6.
Macfarlane C, Budhathoki S, Johnson S, Richardson M, Garner P
Cochrane Database Syst Rev
. 2019 Jan;
1:CD003753.
PMID: 30620051
Background: The Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole co-administered with the microfilaricidal (antifilarial) drugs diethylcarbamazine (DEC) or ivermectin; and recommends albendazole alone in areas where...
7.
Kelly-Hope L, Blundell H, Macfarlane C, Molyneux D
Trends Parasitol
. 2018 Jul;
34(8):694-711.
PMID: 29958813
Lymphatic filariasis (LF) and onchocerciasis are two neglected tropical diseases (NTDs) of public health significance targeted for global elimination. The World Health Organization (WHO) African Region is a priority region,...